# Lipase DC\* FS\*\*

# Order Information

Kit si	ze			
R1	5 x 20 mL	+	R2	1 x 25 mL
R1	1 x 800 mL	+	R2	1 x 200 mL
R1	4 x 20 mL	+	R2	2 x 10 mL
	R1 R1	R1 1 x 800 mL	R1 5 x 20 mL + R1 1 x 800 mL +	R1 5 x 20 mL + R2 R1 1 x 800 mL + R2

## Intended Use

Diagnostic reagent for quantitative in vitro determination of lipase in human serum or heparin plasma on automated photometric systems.

## Summary

Lipases are enzymes which hydrolyze glycerol esters of long fatty acids. The enzyme and its cofactor colipase are produced in the pancreas, lipase being also secreted in small amounts by the salivary glands as well as by gastric, pulmonary and intestinal mucosa. Bile acids and colipase form micellar complexes with the lipids and bind lipase on the substrate/water interface. Determination of lipase is used for investigation of pancreatic disorders. In acute pancreatitis, lipase concentrations rise to 2 - 50 fold the upper reference limit within 4 - 8 hours after the beginning of abdominal pain peaking at 24 hours and decrease within 8 to 14 days. Elevated lipase values may also be observed in chronic pancreatitis and obstruction of the pancreatic duct. [1,2,3,4]

# Method

#### Enzymatic color test

A synthetically produced lipase substrate (1,2-o-dilauryl-racglycero-3-glutaric acid-(6-methylresorufin) ester) is added to a micro-emulsion which is specifically split by lipase in the presence of colipase and bile acids. The combination of lipase and bile acids make this specific and reliable for pancreatic lipase without any reaction due to lipolytic enzymes or esterases. The reagent composition has been thoroughly optimized to avoid serum matrix effects. The generated methylresorufin ester is spontaneously degraded to methylresorufin. The absorbance by this red dye is directly proportional to the lipase activity in the sample. [5,6,7]

Lipase catalyses the reaction:

1,2-o-dilauryl-rac- glycero-3-glutaric acid- (6-methylresorufin) ester	Lipase/Colipase ◀───►	1,2-o-dilauryl-rac- glycerin + Glutaric acid- (6-methylresorufin) ester
Glutaric acid- (6-methylresorufin) ester	spontaneous degradation	Glutaric acid + Methylresorufin

The increase in absorbance is measured photometrically.

### Reagents

#### Components and Concentrations

R1:	Good's buffer	pH 8.0	50 mmol/L
	Taurodesoxycholate		4.3 mmol/L
	Desoxycholate		8.0 mmol/L
	Calcium chloride		15 mmol//L
	Colipase (porcine)		2.2 mg/L
R2:	Tartrate buffer	pH 4.0	7.5 mmol/L
	Taurodesoxycholate		17.2 mmol/L
	Color substrate		≤ 0.65 mmol/L

### Storage and Stability

Reagents are stable up to the date of expiry indicated on the kit, if stored at 2-8°C and contamination is avoided. Do not freeze and protect from light.

**Note:** A slight apparent red precipitate may occur in reagent 2, which does not affect the performance of the test. Please do not resuspend before use.

## Warnings and Precautions

- A Reagent 2: Warning. H319 Causes serious eye irritation. P280 Wear protective gloves/protective clothing/eye protection. P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 If eye irritation persists: Get medical advice/attention.
- Reagent 1 contains sodium azide (0.95 g/L) as preservative. Do not swallow! Avoid contact with skin and mucous membranes.
- 3. Reagent 1 contains animal material. Handle the product as potentially infectious according to universal precautions and good clinical laboratory practice.
- 4. Many other clinical reagents contain lipase or high concentrations of detergents. Avoid contamination and carry over! Special care should be taken in combination with triglycerides, HDL and LDL reagents. Cuvettes and other glassware must be cleaned thoroughly after being used for other assays. In case of automated measurement refer to the instrument manual for special washing programs.
- 5. In very rare cases, samples of patients with gammopathy might give falsified results [8].
- Please refer to the safety data sheets and take the necessary precautions for the use of laboratory reagents. For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examinations and other findings.
- 7. For professional use only.

## Waste Management

Refer to local legal requirements.

### **Reagent Preparation**

The reagents are ready to use.

### **Materials Required**

General laboratory equipment

## Specimen

Human serum or heparin plasma

Stability [9]:		
7 days	at	20 – 25°C
7 days	at	4 – 8°C
1 year	at	–20°C

Only freeze once. Discard contaminated specimens.

## Assay Procedure

#### Basic settings for BioMajesty® JCA-BM6010/C

Wavelength	571/805 nm
Temperature	37°C
Measurement	Kinetic
Sample/Calibrator	2.0 μL
Reagent 1	80 µL
Reagent 2	20 µL
Addition reagent 2	Cycle 19 (286 s)
Absorbance 1	_
Absorbance 2	Cycle 25/30 (367 s/437 s)
Calibration	Linear

### Calculation

With calibrator

Lipase  $[U/L] = \frac{\Delta A/\min Sample}{\Delta A/\min Cal} \times Conc. Cal [U/L]$ 

Conversion Factor Lipase [U/L] x 0.0167 = Lipase [µkat/L]

## **Calibrators and Controls**

DiaSys TruCal U is recommended for calibration. Calibrator values have been made traceable to the molar extinction coefficient of an available measuring method. Use DiaSys TruLab N and P for internal quality control. Use of human based controls is strictly recommended. Each laboratory should establish corrective action in case of deviations in control recovery.

	•			
	Cat. No.	Kit size		
TruCal U	5 9100 99 10 063	20	х	3 mL
	5 9100 99 10 064	6	х	3 mL
TruLab N	5 9000 99 10 062	20	х	5 mL
	5 9000 99 10 061	6	х	5 mL
TruLab P	5 9050 99 10 062	20	х	5 mL
	5 9050 99 10 061	6	х	5 mL

# Performance Characteristics

## Data evaluated on BioMajesty® JCA-BM6010/C

Exemplary data mentioned below may slightly differ in case of deviating measurement conditions.

Measuring range up to 300 U/L.           When values exceed this range, samples should be diluted 1 + 1 with NaCl solution (9 g/L) and the result multiplied by 2.           Limit of detection***         5 U/L           Interfering substance         Interferences 5 10% up to         Analyte concentration [U/L]           Ascorbic acid         60 mg/dL         38.7           60 mg/dL         112         Bilirubin (conjugated)         60 mg/dL         40.1           Bilirubin (unconjugated)         70 mg/dL         39.2         39.2           Hemoglobin         600 mg/dL         40.7         39.2           Hemoglobin         600 mg/dL         40.7         40.7           Hemoglobin         600 mg/dL         410         42.3           Vacetylcysteine (NAC)         2000 mg/dL         42.3           N-acetylcysteine (NAC)         2000 mg/L         39.2           Precision         2000 mg/L         39.2           Within run (n=20)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Mean [U/L]         30.2         59.9         284           Mean [U/L]         30.2         59.9 <th></th> <th>201</th> <th>1.0</th> <th></th> <th></th> <th>]</th>		201	1.0			]	
Interfering substance         Interferences \$ 10% up to         Analyte concentration [U/L]           Ascorbic acid         60 mg/dL         38.7           60 mg/dL         38.7           60 mg/dL         112           Bilirubin (conjugated)         60 mg/dL         40.1           60 mg/dL         110           Bilirubin (unconjugated)         70 mg/dL         39.2           70 mg/dL         110           Hemoglobin         600 mg/dL         40.7           600 mg/dL         40.7         600 mg/dL         40.7           600 mg/dL         116         116         129           Nacetylcysteine (NAC)         2000 mg/L         39.2         39.2           N-acetylcysteine (NAC)         2000 mg/L         39.2         39.2           I0,11).         2000 mg/L         107         500 mg/L         39.2           Precision         2000 mg/L         30.2         39.2           I0,11).         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284 <tr< td=""><td colspan="6"></td></tr<>							
$\leq$ 10% up toconcentration [U/L]Ascorbic acid $60 mg/dL$ $38.7$ $60 mg/dL$ $112$ Bilirubin (conjugated) $60 mg/dL$ $40.1$ $60 mg/dL$ $110$ Bilirubin (unconjugated) $70 mg/dL$ $39.2$ $70 mg/dL$ $110$ Hemoglobin $600 mg/dL$ $40.7$ $600 mg/dL$ $40.7$ $600 mg/dL$ $40.7$ $600 mg/dL$ $416$ Lipemia (triglycerides) $2000 mg/dL$ $42.3$ $2000 mg/dL$ $129$ N-acetylcysteine (NAC) $2000 mg/L$ $39.2$ $2000 mg/L$ $107$ $500 mg/L$ $107$ For further information on interfering substances refer to Young DS [10,11]. $107$ Precision $30.9$ $60.9$ $286$ $CV [\%]$ $1.26$ $0.611$ $0.263$ Mean [U/L] $30.2$ $59.9$ $284$ $CV [\%]$ $2.01$ $1.20$ $1.10$ Mean [U/L] $30.2$ $59.9$ $284$ $CV [\%]$ $2.01$ $1.20$ $1.10$ Mean [U/L] $30.2$ $59.9$ $284$ $CV [\%]$ $2.01$ $1.20$ $1.10$ Method comparison (n=107) $Test x$ $Competitor Lipase (cobas c 311)Test yDiaSys Lipase DC FS (BioMajesty® JCA-BMG010C)Slope0.982-0.168 U/L-0.168 U/L$	Limit of detection***		5 U/L	-			
initial         initial         initial           Bilirubin (conjugated)         60 mg/dL         40.1           60 mg/dL         110           Bilirubin (unconjugated)         70 mg/dL         39.2           70 mg/dL         110           Hemoglobin         600 mg/dL         40.7           600 mg/dL         40.7           600 mg/dL         40.7           600 mg/dL         42.3           2000 mg/dL         42.3           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           N-acetylcysteine (NAC)         2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         30.2         59.9         284	Interfering substance					concentration	
Bilirubin (conjugated)         60 mg/dL         40.1           60 mg/dL         110           Bilirubin (unconjugated)         70 mg/dL         39.2           70 mg/dL         110           Hemoglobin         600 mg/dL         40.7           600 mg/dL         40.7           600 mg/dL         40.7           600 mg/dL         116           Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         Test x         Cobas c 311)         Test x </td <td>Ascorbic acid</td> <td></td> <td>60 m</td> <td colspan="2">g/dL</td> <td colspan="2">38.7</td>	Ascorbic acid		60 m	g/dL		38.7	
60 mg/dL         110           Bilirubin (unconjugated)         70 mg/dL         39.2           70 mg/dL         110           Hemoglobin         600 mg/dL         40.7           600 mg/dL         116           Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         <			-		112		
Bilirubin (unconjugated)         70 mg/dL         39.2           70 mg/dL         110           Hemoglobin         600 mg/dL         40.7           600 mg/dL         116           Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         39.2         39.2           2000 mg/L         129         107           For further information on intertering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         1.10           Method comparison (n=107)         Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope         0.982         1.10           Slo	Bilirubin (conjugated)		60 m	g/dL	40.1		
Image: Note of the second se			60 m	g/dL		110	
Hemoglobin         600 mg/dL         40.7           600 mg/dL         116           Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107         500 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107         500 mg/L         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         1.10           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope         0.982         1.168 U/L	Bilirubin (unconjugated)		70 m	g/dL		39.2	
600 mg/dL         116           Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129         39.2           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107         39.2           Precision         2000 mg/L         107           Within run (n=20)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope           Slope         0.982         -0.168 U/L         -0.168 U/L			70 m	g/dL		110	
Lipemia (triglycerides)         2000 mg/dL         42.3           2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         1.10           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope         0.982           Intercept         -0.168 U/L         -0.168 U/L         -0.168 U/L	Hemoglobin		600 m	ng/dL		40.7	
2000 mg/dL         129           N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         1.10           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope         0.982         1.168 U/L           Intercept         -0.168 U/L         -0.168 U/L         1.100         1.100         1.100			600 m	ng/dL		116	
N-acetylcysteine (NAC)         2000 mg/L         39.2           2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope           Slope         0.982         -         -           Intercept         -0.168 U/L         -         -	Lipemia (triglycerides)		2000 r	ng/dL		42.3	
2000 mg/L         107           For further information on interfering substances refer to Young DS [10,11].         107           Precision         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope           Slope         0.982         -0.168 U/L			2000 r	mg/dL		129	
For further information on interfering substances refer to Young DS [10,11].           Precision           Within run (n=20)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Test x         Competitor Lipase DC FS (BioMajesty® JCA-BM6010C)           Slope         0.982         0.982         0.982         1.168 U/L	N-acetylcysteine (NAC)		2000	mg/L		39.2	
III.         Precision         Within run (n=20)       Sample 1       Sample 2       Sample 3         Mean [U/L]       30.9       60.9       286         CV [%]       1.26       0.611       0.263         Total Precision CLSI (n=80)       Sample 1       Sample 2       Sample 3         Mean [U/L]       30.2       59.9       284         CV [%]       2.01       1.20       1.10         Method comparison (n=107)       Test x       Competitor Lipase (cobas c 311)       Competitor Lipase (cobas c 311)         Test y       DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)       0.982         Slope       0.982			2000	mg/L		107	
Within run (n=20)         Sample 1         Sample 2         Sample 3           Mean [U/L] $30.9$ $60.9$ $286$ CV [%] $1.26$ $0.611$ $0.263$ Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L] $30.2$ $59.9$ $284$ CV [%] $2.01$ $1.20$ $1.10$ Method comparison (n=107)         Test x         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty <sup>®</sup> JCA-BM6010C) $0.982$ Slope $0.982$ $-0.168$ U/L						o Young DS	
Mean [U/L]         30.9         60.9         286           CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         0.982           Slope         0.982         -0.168 U/L	Precision						
CV [%]         1.26         0.611         0.263           Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Competitor Lipase (cbas c 311)         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)           Slope         0.982         -0.168 U/L         -0.168 U/L	Within run (n=20)	S	ample 1	Sample	e 2	Sample 3	
Total Precision CLSI (n=80)         Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)           Test y         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         0.982           Slope         0.982         -0.168 U/L	Mean [U/L]		30.9	60.9		286	
Sample 1         Sample 2         Sample 3           Mean [U/L]         30.2         59.9         284           CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Cobas c 311)           Test x         Competitor Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope         0.982           Intercept         -0.168 U/L         -0.168 U/L         -0.168 U/L	CV [%]		1.26	1.26 0.611		0.263	
CV [%]         2.01         1.20         1.10           Method comparison (n=107)         Competitor Lipase (cobas c 311)         Competitor Lipase (cobas c 311)           Test x         DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Output           Slope         0.982         Intercept         -0.168 U/L		s	Sample 1 Samp		e 2	Sample 3	
Method comparison (n=107)         Test x       Competitor Lipase (cobas c 311)         Test y       DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)         Slope       0.982         Intercept       -0.168 U/L	Mean [U/L]		30.2 59			284	
Test x     Competitor Lipase (cobas c 311)       Test y     DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)       Slope     0.982       Intercept     -0.168 U/L	CV [%]		2.01 1.20		1.10		
(cobas c 311)       Test y     DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)       Slope     0.982       Intercept     -0.168 U/L	Method comparison (n=107)						
(BioMajesty® JCA-BM6010C)           Slope         0.982           Intercept         -0.168 U/L	Test x						
Intercept –0.168 U/L	Test y	est y DiaSys Lipase DC FS (BioMajesty® JCA-BM6010C)			6010C)		
	Slope 0.982						
Coefficient of correlation 0.999	Intercept -0.168 U/L						

\*\*\* according to CLSI document EP17-A2, Vol. 32, No. 8

## Reference Range [12]

≤ 60 U/L ≤ 1.00 µkat/L

Each laboratory should check if the reference ranges are transferable to its own patient population and determine own reference ranges if necessary.

#### Literature

- Lorentz K. Lipase. In: Thomas L, editor. Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 95-7.
- Moss DW, Henderson AR. Digestive enzymes of pancreatic origin. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 689–708.
- 3. Tietz N, Shuey DF. Lipase in serum the elusive enzyme: an overview. Clin Chem 1993; 39: 746-56.
- Lott J, Patel ST, Sawhney AK, Kazmierczak SC, Love JE. Assays of serum lipase: analytical and clinical considerations. Clin Chem 1986; 32: 1290–1302.
- Leybold A, Junge W. Importance of colipase for the measurement of serum lipase activity. Adv Clin Enzymol 1986;4: 60-7.
- 6. Borgström B. The action of bile salts and other detergents on pancreatic lipase and the interaction with colipase. Biochimica et Biophysika Acta 1977; 488: 381-91.
- Gargouri Y, Julien R, Bois A, Verger R, Sarda L. Studies on the detergent inhibition of pancreatic lipase activity. J of Lipid Research 1983; 24: 1336-42.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: Mechanism, detection and prevention. Clin Chem Lab Med 2007; 45(9): 1240–1243.
- 9. Guder WG, Zawta B et al. The Quality of Diagnostic Samples. 1st ed. Darmstadt: GIT Verlag; 2001; p. 36-7.
- Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington, DC: The American Association for Clinical Chemistry Press 2000.
- Young DS. Effects on Clinical Laboratory Tests Drugs Disease, Herbs & Natural Products, https://clinfx.wiley.com/ aaccweb/aacc/, accessed in August 2021. Published by AACC Press and John Wiley and Sons, Inc.
- Junge W, Abicht K, Goldman J. Evaluation of the colorimetric liquid assay for pancreatic lipase on Hitachi analyzers in 7 clinical centres in Europe. Clin Chem Lab Med 1999; 37, Special suppl: 469.



DiaSys Diagnostic Systems GmbH Alte Strasse 9 65558 Holzheim Germany www.diasys-diagnostics.com

\* Direct Color

\*\* Fluid Stable